MiniMed Faces FDA Panel For Consumer Glucose Sensor; Dampens Outlook

MiniMed's home-use continuous glucose monitoring system (CGMS) could be reviewed by FDA's Clinical Chemistry and Clinical Toxicology Panel as early as May 9, the company says.

More from Archive

More from Medtech Insight